BBHC
ACOR

Brown Brothers Harriman & Co’s Acorda Therapeutics ACOR Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed -$4K – 901
2016
Q4 		$4K Hold
2
– – ﹤0.01% 796
2016
Q3 		$4K Hold
2
– – ﹤0.01% 716
2016
Q2 		$5K Buy
+2
New +$6.5K ﹤0.01% 721
2015
Q1 		– Sell
-1
Closed -$5K – 870
2014
Q4 		$5K Buy
+1
New +$4.29K ﹤0.01% 756
2013
Q4 		– Sell
-1
Closed -$5K – 718
2013
Q3 		$5K Buy
+1
New +$4.31K ﹤0.01% 620

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Brown Brothers Harriman & Co's ACOR Position: Q1 2017 in Review

Brown Brothers Harriman & Co sold out of Acorda Therapeutics (ACOR) in Q1 2017, closing a stake of 2 shares — an estimated $4K sold.

Brown Brothers Harriman & Co first reported a position in ACOR in Q3 2013 and held it in 5 quarters. The position peaked at $5K in Q2 2016. 178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • Brown Brothers Harriman & Co reported no remaining Acorda Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 2 Acorda Therapeutics shares in Q1 2017, an estimated $4K.
  • Brown Brothers Harriman & Co first reported a position in Acorda Therapeutics in Q3 2013 and held it in 5 quarters.
  • Brown Brothers Harriman & Co's Acorda Therapeutics position peaked at $5K in Q2 2016.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2017, filed 12 May 2017.